Systemic corticosteroids
Phase 3Small molecule
Merck & Co.Systemic corticosteroids is one of 35 small molecule programs targeting Ankylosing Spondylitis. It is currently in Phase 3.
2
Indications
5
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
29 competitors in Ankylosing Spondylitis
#DrugCompanyPhaseTrials
1Humira
NovartisApproved
Cosentyx
NovartisApproved
Trexall
Jazz PharmaceuticalsApproved
Azulfidine
PfizerApproved
Voltaren
NovartisApproved
Plaquenil
Jazz PharmaceuticalsApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Aleve
Jazz PharmaceuticalsApproved
Cytotec
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ankylosing Spondylitis1 trial
Characteristics of Ankylosing Spondylitis Associated Uveitis
Completed·—··NCT07113834·22 enrolled
Recurrence1 trial
Steroid1 trial
How Long Should we Give Steroids for Patients With Severe PCP
Not yet recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT07328984·416 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Systemic corticosteroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company